217 related articles for article (PubMed ID: 21836608)
1. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.
Satoh Y; Matsumura I; Tanaka H; Harada H; Harada Y; Matsui K; Shibata M; Mizuki M; Kanakura Y
Leukemia; 2012 Feb; 26(2):303-11. PubMed ID: 21836608
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
5. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
6. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.
Matsuura S; Komeno Y; Stevenson KE; Biggs JR; Lam K; Tang T; Lo MC; Cong X; Yan M; Neuberg DS; Zhang DE
Blood; 2012 Nov; 120(19):4028-37. PubMed ID: 22919028
[TBL] [Abstract][Full Text] [Related]
7. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
8. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia.
Foster N; Paulsson K; Sales M; Cunningham J; Groves M; O'Connor N; Begum S; Stubbs T; McMullan DJ; Griffiths M; Pratt N; Tauro S
Br J Haematol; 2010 Mar; 148(6):938-43. PubMed ID: 20064152
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
Matsumura T; Nakamura-Ishizu A; Muddineni SSNA; Tan DQ; Wang CQ; Tokunaga K; Tirado-Magallanes R; Sian S; Benoukraf T; Okuda T; Asou N; Matsuoka M; Osato M; Suda T
Blood; 2020 Oct; 136(17):1919-1932. PubMed ID: 32573733
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.
Tonks A; Pearn L; Musson M; Gilkes A; Mills KI; Burnett AK; Darley RL
Leukemia; 2007 Dec; 21(12):2495-505. PubMed ID: 17898786
[TBL] [Abstract][Full Text] [Related]
13. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
Harada H
Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
[No Abstract] [Full Text] [Related]
14. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
15. Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions.
Behrens K; Triviai I; Schwieger M; Tekin N; Alawi M; Spohn M; Indenbirken D; Ziegler M; Müller U; Alexander WS; Stocking C
Blood; 2016 Jun; 127(26):3369-81. PubMed ID: 27076172
[TBL] [Abstract][Full Text] [Related]
16. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
17. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
18. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
19. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
[TBL] [Abstract][Full Text] [Related]
20. Familial myelodysplasia and acute myeloid leukaemia--a review.
Owen C; Barnett M; Fitzgibbon J
Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
